Price Disclosure Reductions for 2022 April Cycle

Page last updated: 28 February 2022

This summary only includes medicines taking a price disclosure reduction on 1 April 2022. The determined price disclosure outcomes for this cycle were calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 2017 (the Regulations).

The outcomes below show percentage (%) price differences and Approved Ex‑Manufacturer level prices. They do not include fees and mark-ups. Information about publication of prices including fees and mark-ups is set out below.

Flow-on Reductions for F2 Combination Items

Responsible persons with a brand of an F2 combination item should note that:

  • if an F2 combination item is listed below, it has met the criteria for a direct reduction. However, this reduction may not take effect on 1 April 2022 if the price of a component ingredient is also reduced and flowing on this component price reduction results in a lower price; or
  • if an F2 combination item did not receive a direct price disclosure reduction, it may still receive a price reduction as a result of the flow-on of the price of a component ingredient that is taking a price disclosure reduction.

Outcomes for flow-on price disclosure reductions to F2 combination items have been communicated to responsible persons with brands of affected drugs.

Legal Determination & Next Steps

The weighted average disclosed prices for each brand, including brands with a determination but no reduction, can be found in the legal determination on the Federal Register of Legislation website. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Brands listed in Schedule 2 of the determination will not take a price disclosure reduction.

Any new brands of existing pharmaceutical items with a determination in Schedule 1 that listed after 30 September 2021 will also take the reduction on 1 April 2022 under section 99ADHA of the Act.

An industry agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process

The date for lodgement of disputes was by 5:00pm AEST on 17 December 2021. 

Indicative prices for 1 April 2022 (including price to pharmacy, dispensed price for maximum quantity and price premiums) were published in January 2022.

Final prices for 1 April 2022 reductions (including all price to pharmacy, dispensed price for maximum quantity/amount and price premiums) will be available from March 2022.

2022 April Cycle Outcomes Summary

2022 April cycle Outcomes Summary - Data collection period 1 April 2021 - 30 September 2021

Legal Instrument Drug

Legal Instrument MoA

Legal Instrument Form

Average AEMP

WAPD
(%)
(Drug/MoA)

WADP potential
April '22
 AEMP

October '21 AEMP

Percentage difference between October '21  and April '22 AEMP

Calculations based on:
OWAPD = all brand data
GWAPD = originator brand data removed
Does not meet 30 month clock

Unadjusted Price Reduction threshold (%)

Acamprosate

Oral

Tablet (enteric coated) containing acamprosate calcium 333 mg

$95.53

25.66%

$71.02

$84.63

16.08%

GWAPD

10

Alendronic acid with colecalciferol and calcium

Oral

Pack containing 4 tablets containing alendronic acid 70 mg (as alendronate sodium) with 140 micrograms colecalciferol and 48 tablets calcium 500 mg (as carbonate)

$10.92

77.56%

$2.45

$10.92

77.56%

OWAPD

30

Arsenic

Injection

Injection concentrate containing arsenic trioxide 10 mg in 10 mL

$2,435.03

49.01%

$1,241.62

$2,435.03

49.01%

Does not meet 30 month clock

10

Buprenorphine

Transdermal

Transdermal patch 10 mg

$20.42

15.31%

$17.29

$20.42

15.33%

GWAPD

10

Buprenorphine

Transdermal

Transdermal patch 15 mg

$25.96

15.31%

$21.99

$25.96

15.29%

GWAPD

10

Buprenorphine

Transdermal

Transdermal patch 20 mg

$31.51

15.31%

$26.69

$31.51

15.30%

GWAPD

10

Buprenorphine

Transdermal

Transdermal patch 25 mg

$36.76

15.31%

$31.13

$36.76

15.32%

GWAPD

10

Buprenorphine

Transdermal

Transdermal patch 30 mg

$42.01

15.31%

$35.58

$42.01

15.31%

GWAPD

10

Buprenorphine

Transdermal

Transdermal patch 40 mg

$52.51

15.31%

$44.47

$52.51

15.31%

GWAPD

10

Buprenorphine

Transdermal

Transdermal patch 5 mg

$11.34

15.31%

$9.60

$11.34

15.34%

GWAPD

10

Cabazitaxel

Injection

Concentrated injection 60 mg (as acetone solvate) in 1.5 mL, with diluent

$946.16

37.08%

$595.32

$946.16

37.08%

Does not meet 30 month clock

10

Cabazitaxel

Injection

Solution concentrate for I.V. infusion 60 mg in 6 mL

$946.16

37.08%

$595.32

$946.16

37.08%

Does not meet 30 month clock

10

Docetaxel

Injection

Solution concentrate for I.V. infusion 160 mg in 8 mL

$48.24

30.86%

$33.35

$48.24

30.87%

OWAPD

30

Docetaxel

Injection

Solution concentrate for I.V. infusion 80 mg in 4 mL

$24.12

30.86%

$16.68

$24.12

30.85%

OWAPD

30

Erlotinib

Oral

Tablet 100 mg (as hydrochloride)

$669.02

20.56%

$531.47

$669.02

20.56%

Does not meet 30 month clock

10

Erlotinib

Oral

Tablet 150 mg (as hydrochloride)

$827.66

20.56%

$657.49

$827.66

20.56%

Does not meet 30 month clock

10

Erlotinib

Oral

Tablet 25 mg (as hydrochloride)

$184.33

20.56%

$146.43

$184.33

20.56%

Does not meet 30 month clock

10

Ezetimibe

Oral

Tablet 10 mg

$10.83

23.54%

$8.28

$9.57

13.48%

GWAPD

10

Fluorouracil

Injection

Injection 2500 mg in 50 mL

$17.73

31.70%

$12.11

$17.73

31.70%

OWAPD

30

Fluorouracil

Injection

Injection 500 mg in 10 mL

$3.55

31.70%

$2.42

$3.55

31.83%

OWAPD

30

Fluorouracil

Injection

Injection 5000 mg in 100 mL

$35.46

31.70%

$24.22

$35.46

31.70%

OWAPD

30

Hyoscine

Injection

Injection containing hyoscine butylbromide 20 mg in 1 mL

$10.03

34.53%

$6.57

$8.79

25.26%

GWAPD

10

Lurasidone

Oral

Tablet containing lurasidone hydrochloride 40 mg

$46.48

17.04%

$38.56

$46.48

17.04%

Does not meet 30 month clock

10

Lurasidone

Oral

Tablet containing lurasidone hydrochloride 80 mg

$92.96

17.04%

$77.12

$92.96

17.04%

Does not meet 30 month clock

10

Moxonidine

Oral

Tablet 200 micrograms

$6.36

10.87%

$5.67

$6.36

10.85%

GWAPD

10

Moxonidine

Oral

Tablet 400 micrograms

$10.84

10.87%

$9.66

$10.84

10.89%

GWAPD

10

Nebivolol

Oral

Tablet 1.25 mg (as hydrochloride)

$14.73

20.15%

$11.76

$14.73

20.16%

GWAPD

10

Nebivolol

Oral

Tablet 10 mg (as hydrochloride)

$41.56

20.15%

$33.19

$41.56

20.14%

GWAPD

10

Nebivolol

Oral

Tablet 5 mg (as hydrochloride)

$36.78

20.15%

$29.37

$36.78

20.15%

GWAPD

10

Nevirapine

Oral

Tablet 200 mg

$102.33

30.13%

$71.50

$102.33

30.13%

GWAPD

30

Nevirapine

Oral

Tablet 400 mg (extended release)

$102.33

30.13%

$71.50

$102.33

30.13%

GWAPD

30

Pegfilgrastim

Injection

Injection 6 mg in 0.6 mL single use pre-filled syringe

$346.39

48.56%

$178.18

$346.39

48.56%

GWAPD

30

Posaconazole

Oral

Tablet (modified release) 100 mg

$407.89

24.15%

$309.38

$407.89

24.15%

Does not meet 30 month clock

10

Rituximab

Injection

Solution for I.V. infusion 100 mg in 10 mL

$310.53

56.23%

$135.92

$216.17

37.12%

Does not meet 30 month clock

10

Rituximab

Injection

Solution for I.V. infusion 500 mg in 50 mL

$776.32

56.23%

$339.80

$540.43

37.12%

Does not meet 30 month clock

10

Tenofovir with emtricitabine

Oral

Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg

$53.81

34.77%

$35.10

$53.81

34.77%

OWAPD

30

Tenofovir with emtricitabine

Oral

Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg

$53.81

34.77%

$35.10

$53.81

34.77%

OWAPD

30

Tenofovir with emtricitabine

Oral

Tablet containing tenofovir disoproxil phosphate 291 mg with emtricitabine 200 mg

$53.81

34.77%

$35.10

$53.81

34.77%

OWAPD

30

Tenofovir with emtricitabine

Oral

Tablet containing tenofovir disoproxil succinate 301 mg with emtricitabine 200 mg

$53.81

34.77%

$35.10

$53.81

34.77%

OWAPD

30

Tenofovir with emtricitabine and efavirenz

Oral

Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg and efavirenz 600 mg

$270.88

13.69%

$233.80

$270.88

13.69%

Does not meet 30 month clock

10

Trastuzumab

Injection

Powder for I.V. infusion 150 mg

$375.39

36.86%

$237.02

$315.26

24.82%

Does not meet 30 month clock

10

Trastuzumab

Injection

Powder for I.V. infusion 420 mg

$1,051.09

36.86%

$663.66

$882.71

24.82%

Does not meet 30 month clock

10

Zoledronic acid

Injection

Injection concentrate for I.V. infusion 4 mg (as monohydrate) in 5 mL

$72.80

30.99%

$50.24

$72.80

30.99%

GWAPD

30

Zoledronic acid

Injection

Solution for I.V. infusion 4 mg (as monohydrate) in 100 mL

$72.80

30.99%

$50.24

$72.80

30.99%

GWAPD

30

Zoledronic acid

Injection

Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL

$97.47

30.99%

$67.26

$97.47

30.99%

GWAPD

30